Evolus (EOLS) Net Income towards Common Stockholders (2017 - 2026)
Evolus (EOLS) posted Net Income towards Common Stockholders of -$10.7 million for Q1 2026, down 8310.77% on a QoQ basis from $130000.0 in Q4 2025, and up 43.5% year-over-year from -$7.4 million in Q1 2025.
Evolus (EOLS) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Evolus' Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$10.7 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 43.5% year-over-year to -$10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.4 million (up 22.74% YoY) and the FY2025 annual result came in at -$51.6 million, down 2.42% from the prior year.
- Net Income towards Common Stockholders was -$10.7 million for Q1 2026 at Evolus, down from $130000.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $130000.0 in Q4 2025 and bottomed at -$23.5 million in Q2 2022.
- A 5-year average of -$14.6 million and a median of -$15.7 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 373.41% — and 2025, when it soared 101.91%.
- Evolus' Net Income towards Common Stockholders stood at -$13.2 million in 2022, then advanced by 10.13% to -$11.8 million in 2023, then soared by 42.6% to -$6.8 million in 2024, then jumped by 101.91% to $130000.0 in 2025, then plunged by 8310.77% to -$10.7 million in 2026.
- Business Quant data shows EOLS's Net Income towards Common Stockholders at -$10.7 million in Q1 2026, $130000.0 in Q4 2025, and -$15.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Evolus | 393.73 Mn | 343.94 Mn | 48.90 Mn | -10.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.67 Mn |
| Dec 31, 2025 | 130,000.00 |
| Sep 30, 2025 | -15.74 Mn |
| Jun 30, 2025 | -17.14 Mn |
| Mar 31, 2025 | -18.89 Mn |
| Dec 31, 2024 | -6.79 Mn |
| Sep 30, 2024 | -19.17 Mn |
| Jun 30, 2024 | -11.35 Mn |
| Mar 31, 2024 | -13.11 Mn |
| Dec 31, 2023 | -11.83 Mn |
| Sep 30, 2023 | -16.92 Mn |
| Jun 30, 2023 | -18.14 Mn |
| Mar 31, 2023 | -14.79 Mn |
| Dec 31, 2022 | -13.16 Mn |
| Sep 30, 2022 | -20.28 Mn |
| Jun 30, 2022 | -23.47 Mn |
| Mar 31, 2022 | -17.50 Mn |
| Dec 31, 2021 | -18.18 Mn |
| Sep 30, 2021 | -19.43 Mn |
| Jun 30, 2021 | -15.60 Mn |